Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, July 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies fo
Board Observer of Taysha Gene Therapies Picks Up 5.7% More Stock
Those following along with Taysha Gene Therapies, Inc. (NASDAQ:TSHA) will no doubt be intrigued by the recent purchase of shares by Paul Manning, Board Observer of the company, who spent a stonking US
Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit
Taysha Gene Therapies Insider Bought Shares Worth $2,999,999, According to a Recent SEC Filing
Paul B Manning, 10% Owner, on June 27, 2024, executed a purchase for 1,333,333 shares in Taysha Gene Therapies (TSHA) for $2,999,999. Following the Form 4 filing with the SEC, Manning has control over
Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Cuts Target Price to $7
Piper Sandler analyst Christopher Raymond maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating, and adjusts the target price from $9 to $7.According to TipRanks data, the analyst has a success
Express News | Piper Sandler Maintains Overweight on Taysha Gene Therapies, Lowers Price Target to $7
Taysha Gene Therapies (TSHA) Gets a Buy From Piper Sandler
Express News | Taysha Gene Therapies Inc : Piper Sandler Cuts Target Price to $7 From $9
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 33%
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shareholders won't be pleased to see that the share price has had a very rough month, dropping 33% and undoing the prior period's positive performance. Of
Express News | Taysha Gene Therapies Inc : BMO Initiates Coverage With Outperform Rating; Target Price $5
Taysha Gene Therapies Initiated at Outperform by BMO Capital
Taysha Gene Therapies Initiated at Outperform by BMO Capital
Express News | BMO Capital Initiates Coverage On Taysha Gene Therapies With Outperform Rating, Announces Price Target of $5
BMO Capital Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating, Announces Target Price $5
BMO Capital analyst Evan Seigerman initiates coverage on $Taysha Gene Therapies(TSHA.US)$ with a buy rating, and sets the target price at $5.According to TipRanks data, the analyst has a success rate
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Health care stocks were mixed pre-bell Wednesday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.5% recently. Savara (SVRA) rose past 17% aft
Express News | Taysha Gene Therapies Inc - Expects Approximately $75 Million Gross Proceeds From Offering
Express News | Taysha Gene Therapies Inc - to Issue Pre-Funded Warrants for About 19 Mln Shares at $2.249 Each
Express News | Taysha Gene Therapies Inc - Prices Public Offering of 14.4 Mln Shares at $2.25 per Share
Express News | Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Top Premarket Decliners
GRI Bio (GRI) shares were down nearly 30% in recent Wednesday premarket activity, reversing Tuesday's 11% rise. Sypris Solutions (SYPR) stock was more than 16% lower, extending Tuesday's 1.1% loss. Ta